Select Page

BANTAM PHARMACEUTICAL

Bantam Pharmaceutical is developing small molecule oncology therapeutics with a novel mechanism of action that modulate key elements of cancer cell metabolism critical for cancer development and growth. Bantam’s orally available lead molecule, BTM-3528, targets a subset of solid tumors and hematologic cancers encompassing a $10 billion oncology market opportunity. With $10 million in funding raised to date, Bantam Pharmaceutical is seeking partners and investors as it rapidly advances BTM-3528 towards pivotal Phase I clinical trials.

A NOVEL MECHANISM OF ACTION

The molecular action of Bantam’s compounds are tumor specific and have no demonstrable effect on normal cells. The compounds display exceptional in vivo activity in tumor xenograft models including potent activity against KRAS mutant solid tumors, including but not limited to colorectal and lung cancers, as well as lymphoid cancers. The mechanism by which BTM-3528 anti-cancer is active is mediated through a cascade of events involving ATF4 mediated Integrated Stress Respsonse (ISR) pathway. Our data to date show that the mechanism of action for BTM-3528 is novel and distinct from other known targeted therapeutics, including histone deacetylase, proteasome, and kinase inhibitors.

PATENTED TECHNOLOGY

Bantam has exclusive rights to BTM-3528 and associated chemical space for all applications. In addition, Bantam owns recently filed patent applications that feature additional claims related to the mechanism and all routes of administration. These filings will support patent protection for BTM-3528 and any derivative products through 2037.

UNMET ONCOLOGY NEEDS

Bantam Pharmaceutical is committed to developing therapeutics to address key unmet cancer patient needs with proof of concept clinical studies focused on lymphoid cancers and KRAS mutated solid tumors.

 

SEEKING PARTNERS AND INVESTORS

Bantam is presently seeking financing to initiate and complete CMC development, progress BTM-3528 through IND-enabling studies and Phase Ia/Ib clinical studies, and bring the Company to an exit/partnering event with a significant investor ROI.

Please pardon our appearance while we remodel our website.

In the meantime for more information please fill out and submit the form, or contact:

Michael Luther, CEO
(646) 598-4823
mluther@bantampharma.com

Contact Us

9 + 8 =